MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification

Shi, Wenjing; Tang, Yongzhe; Lü, Jing; Zhuang, Yihui; Wang, Jie

doi:10.1186/s13578-022-00772-z

Cited by 31 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decisive role of m6A modification in cancer progression has been widely reported in recent years 19 , 45 . m6A modification is dynamically regulated by its writers, erasers, and readers, which are involved in the progression of cancer metastasis 13 , 16 , 46 , including BC 15 , 47 - 50 . Here, we found that the m6A reader IGF2BP1 was upregulated in BC tissues, especially BC metastatic lesions, and was associated with a poor prognosis of BC.…”

Section: Discussionmentioning

confidence: 99%

Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner

Shi¹,

Yin²,

Ye³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Metastasis leads to the vast majority of breast cancer mortality. Increasing evidence has shown that N6-methyladenosine (m6A) modification and its associated regulators play a pivotal role in breast cancer metastasis. Here, we showed that overexpression of the m6A reader IGF2BP1 was clinically correlated with metastasis in breast cancer patients. Moreover, IGF2BP1 promoted distant metastasis in vitro and in vivo. Mechanistically, we first identified USP10 as the IGF2BP1 deubiquitinase. USP10 can bind to, deubiquitinate, and stabilize IGF2BP1, resulting in its higher expression level in breast cancer. Furthermore, by MeRIP-seq and experimental verification, we found that IGF2BP1 directly recognized and bound to the m6A sites on CPT1A mRNA and enhanced its stability, which ultimately mediated IGF2BP1-induced breast cancer metastasis. In clinical samples, USP10 levels correlated with IGF2BP1 and CPT1A levels, and breast cancer patients with high levels of USP10, IGF2BP1, and CPT1A had the worst outcome. Therefore, these findings suggest that the USP10/IGF2BP1/CPT1A axis facilitates breast cancer metastasis, and this axis may be a promising prognostic biomarker and therapeutic target for breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner

Shi¹,

Yin²,

Ye³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…In addition to pancreatic cancer, MIR210HG can also promote various cancer types, such as breast cancer, gastric cancer, and ovarian cancer (53)(54)(55). Additionally, previous studies have identified seven GT-related lncRNAs as prognostic factors in colon cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…In pancreatic cancer, MIR210HG acted as oncogenic regulator and promoted pancreatic cell proliferation and migration ( 52 ). In addition to pancreatic cancer, MIR210HG can also promote various cancer types, such as breast cancer, gastric cancer, and ovarian cancer ( 53 – 55 ). Additionally, previous studies have identified seven GT-related lncRNAs as prognostic factors in colon cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Glycosyltransferase-related long non-coding RNA signature predicts the prognosis of colon adenocarcinoma

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

PurposeColon adenocarcinoma (COAD) is the most common type of colorectal cancer (CRC) and is associated with poor prognosis. Emerging evidence has demonstrated that glycosylation by long noncoding RNAs (lncRNAs) was associated with COAD progression. To date, however, the prognostic values of glycosyltransferase (GT)-related lncRNAs in COAD are still largely unknown.MethodsWe obtained the expression matrix of mRNAs and lncRNAs in COAD from The Cancer Genome Atlas (TCGA) database. Then, the univariate Cox regression analysis was conducted to identify 33 prognostic GT-related lncRNAs. Subsequently, LASSO and multivariate Cox regression analysis were performed, and 7 of 33 GT-related lncRNAs were selected to conduct a risk model. Gene set enrichment analysis (GSEA) was used to analyze gene signaling pathway enrichment of the risk model. ImmuCellAI, an online tool for estimating the abundance of immune cells, and correlation analysis were used to explore the tumor-infiltrating immune cells in COAD. Finally, the expression levels of seven lncRNAs were detected in colorectal cancer cell lines by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).ResultsA total of 1,140 GT-related lncRNAs were identified, and 7 COAD-specific GT-related lncRNAs (LINC02381, MIR210HG, AC009237.14, AC105219.1, ZEB1-AS1, AC002310.1, and AC020558.2) were selected to conduct a risk model. Patients were divided into high- and low-risk groups based on the median of risk score. The prognosis of the high-risk group was worse than that of the low-risk group, indicating the good reliability and specificity of our risk model. Additionally, a nomogram based on the risk score and clinical traits was built to help clinical decisions. GSEA showed that the risk model was significantly enriched in metabolism-related pathways. Immune infiltration analysis revealed that five types of immune cells were significantly different between groups, and two types of immune cells were negatively correlated with the risk score. Besides, we found that the expression levels of these seven lncRNAs in tumor cells were significantly higher than those in normal cells, which verified the feasibility of the risk model.ConclusionThe efficient risk model based on seven GT-related lncRNAs has prognostic potential for COAD, which may be novel biomarkers and therapeutic targets for COAD patients.

show abstract

“… 42 , 43 , 44 m 6 A methylation relies on the readers such as YTHDC2 and other m 6 A recognition proteins including heterogeneous nuclear ribonucleoprotein A2B1, heterogeneous nuclear ribonucleoproteins C, fragile X mental retardation protein, IGF2BP , and many others. 45 , 46 , 47 , 48 , 49 , 50 , 51 …”

Section: A Rna Methylation Modificationmentioning

confidence: 99%

N6-methyladenine RNA Methylation Epigenetic Modification and Kidney Diseases

Luan

Kopp

Zhou

2023

Kidney International Reports

View full text Add to dashboard Cite

MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification

Cited by 31 publications

References 28 publications

Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner

Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner

Glycosyltransferase-related long non-coding RNA signature predicts the prognosis of colon adenocarcinoma

N6-methyladenine RNA Methylation Epigenetic Modification and Kidney Diseases

Contact Info

Product

Resources

About